Cue Biopharma (CUE) is scheduled to provide a quarterly update after the bell today (details here).
It’s possible the company will use it as a venue to provide the highly anticipated interim data on CUE-101 for the treatment of HPV-driven cancers.
Personally, I believe the company would maximize visibility and impact by revealing the data in a few weeks at the ASCO conference instead.
Regardless of where and when it’s revealed, all the evidence points to it being overwhelmingly positive.
Now, by saying that I realize it makes CUE sound like a sure thing. We know sure things don’t exist in the markets, particularly biotechs. But the evidence hiding in plain sight substantiates my strong conviction.
This content is reserved for subscribers. To gain immediate access to our 100% independent research on the top tech trends and companies before they become household names, consider subscribing here.
For a limited time only you can use Coupon Code DTR50 to receive 50% off a quarterly or annual subscription.